Select Page
Jeremy Slawin, MD, MBA

Jeremy Slawin, MD, MBA

Baylor College of Medicine

Houston, Texas

Jeremy Slawin, MD, MBA, is an Assistant Professor of Urology at Baylor College of Medicine in Houston, Texas and a staff surgeon at the Michael E. DeBakey VA Medical Center in Houston, Texas. Dr. Slawin earned his MD from Baylor College of Medicine and his MBA from Rice University. Dr. Slawin completed a fellowship in robotic surgery and urologic oncology at Houston Methodist Hospital. Dr. Slawin completed his residency in urology at the NYU Grossman School of Medicine at Langone Medical Center at Bellevue Hospital and at the Manhattan VA Hospital in New York City, New York.

Disclosures:

Talks by Jeremy Slawin, MD, MBA

Competing Risks for Small Renal Masses

Competing Risks for Small Renal Masses

Posted by | Aug 2024

Jeremy Slawin, MD, MBA, addresses competing risks in managing small renal masses (SRM), balancing treatment versus active surveillance of low risk disease. He begins by illustrating the characteristics of SRMs.

Dr. Slawin recognizes the low metastatic potential of SRMs. In combination with their average slow growth rate, SRMs under 3cm often do not need intervention beyond surveillance.

Dr. Slawin concludes by comparing the 5-year survival rates of patients with SRM versus all other causes. He offers online tools, like the RCC Competing Risk Model, and framing techniques to help clinicians effectively communicate the risks of SRM treatments to individual patients.

Read More
Gleason 6 (GG1) – Should It Be Called Prostate Cancer?

Gleason 6 (GG1) – Should It Be Called Prostate Cancer?

Posted by | Feb 2024

Jeremy Slawin, MD, MBA, presents arguments for and against the reclassification of Gleason 6 (GG1) as something other than prostate cancer. He begins with a brief overview of the definition and perception of prostate cancer, and the psychological burdens and implications which come with cancer diagnoses.

Dr. Slawin then addresses the growing momentum in favor of a change in nomenclature for Gleason 6 (GG1) that does not include the word “cancer,” as has been done for diseases like noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP), formerly called papillary thyroid cancer. Dr. Slawin presents data supporting the idea that GG1 is closer to pre-cancer in clinical behavior, detection, and management, and that calling it a cancer may drive overtreatment of GG1.

Dr. Slawin then turns to arguments against the reclassification of GG1. He addresses the issue of undersampling in biopsies which lead to GG1 diagnoses, the risk of under-grading, and how failing to call GG1 “cancer” could give a false perception of risk and lower the already-low patient compliance rates in active surveillance treatment.

Dr. Slawin concludes by giving his perspective on the issue of changing the nomenclature for GG1. He, along with most pathologists, is not in favor of reclassifying GG1, and leads a Q&A with the audience to gather their perspectives.

Read More

Join the GRU Community

- Why Join? -